ライフサイエンスコーパス: bowel disease

1 tial diagnosis and follow-up of inflammatory bowel disease.

2 inflammatory conditions such as inflammatory bowel disease.

3 n cancer (CAC) in patients with inflammatory bowel disease.

4 ne-mediated diseases, including inflammatory bowel disease.

5 ibute to events associated with inflammatory bowel disease.

6 disease status in patients with inflammatory bowel disease.

7 t leads to pathogenesis such as inflammatory bowel disease.

8 thobiology between COVID-19 and inflammatory bowel disease.

9 ion cohort of 178 patients with inflammatory bowel disease.

10 immune responses as observed in inflammatory bowel disease.

11 seases such as bowel cancer and inflammatory bowel disease.

12 sia and cancer in patients with inflammatory bowel disease.

13 rine colitis model and in human inflammatory bowel disease.

14 dysbiosis that occurs in human inflammatory bowel disease.

15 closest genetic relatedness to inflammatory bowel disease.

16 den of illness in patients with Inflammatory Bowel Disease.

17 sing self-care in patients with inflammatory bowel disease.

18 sition changes in patients with Inflammatory Bowel Disease.

19 CD4(+) T cell transfer model of inflammatory bowel disease.

20 f self-care among patients with inflammatory bowel disease.

21 plicated in the pathogenesis of inflammatory bowel disease.

22 uch as rheumatoid arthritis and inflammatory bowel disease.

23 bially produced metabolites and inflammatory bowel disease.

24 of surveillance colonoscopy in inflammatory bowel disease.

25 g type 2 diabetes, obesity, and inflammatory bowel disease.

26 orthy pathogen in patients with inflammatory bowel disease.

27 helium from luminal threats and inflammatory bowel disease.

28 ing immunological diseases like inflammatory bowel disease.

29 of microbiotas from humans with inflammatory bowel disease.

30 a morphology code suggestive of inflammatory bowel disease.

31 SE patients do not develop significant small bowel disease.

32 the detection and follow-up of inflammatory bowel disease.

33 Galectin-9 is a risk gene in inflammatory bowel disease.

34 ich diet modulates the onset of inflammatory bowel disease.

35 for therapeutic intervention in inflammatory bowel disease.

36 linked to pathologies including inflammatory bowel disease.

37 S in HIV-negative patients with inflammatory bowel disease.

38 nce of childbearing for risk of inflammatory bowel disease.

39 flammatory conditions including inflammatory bowel disease.

40 ified as a gut damage marker in inflammatory bowel diseases.

41 ensitivity (VH) with underlying inflammatory bowel diseases.

42 n investigated in patients with inflammatory bowel diseases.

43 and phosphorylation patterns in inflammatory bowel diseases.

44 ncommunicable disorders such as inflammatory bowel diseases.

45 ic inflammation, as observed in inflammatory bowel diseases.

46 responses, most notably during inflammatory bowel diseases.

47 ght be used in the treatment of inflammatory bowel diseases.

48 as cancer, cystic fibrosis, and inflammatory bowel diseases.

49 ents at risk for development of inflammatory bowel diseases.

50 wel diagnosis and monitoring in inflammatory bowel diseases.

51 y apoptotic enterocolopathy and inflammatory bowel diseases.

52 which have also been linked to inflammatory bowel diseases.

53 as high as 78% in patients with inflammatory bowel disease(2).

54 kidney disease, 3.9% (n=18) and inflammatory bowel disease, 21.9% (n=101).

55 ge 43 years, 58% male, 60% with inflammatory bowel disease, 46% on ursodeoxycholic acid).

56 minal pain ($10.2 billion), and inflammatory bowel disease ($7.2 billion) were the most expensive.

57 (23.2%) and family history with inflammatory bowel diseases (9.4%) and celiac disease (7.3%) were hig

58 utic strategy for patients with inflammatory bowel disease(9).

59 raft-versus-host disease(8) and inflammatory bowel disease(9,10).

60 suggest an association between inflammatory bowel disease, a chronic autoimmune condition linked to

61 abolic pathways associated with inflammatory bowel disease across two completely independent studies.

62 is in the gut microbiome during inflammatory bowel disease activity.

63 65%) matched controls developed inflammatory bowel disease (adjusted HR, 3.29; 95% confidence interva

64 We also explored whether inflammatory bowel disease affects development of ESKD in IgA nephrop

65 isotype, whereas patients with inflammatory bowel disease also produce high concentrations of IgG.

66 Inflammatory bowel disease also was more common before a confirmed Ig

67 multiple sclerosis, psoriasis, inflammatory bowel disease, among others) and in the host response to

68 The presence of a concomitant inflammatory bowel disease, an autoimmune hepatitis or immunosuppress

69 rther demonstrated in models of inflammatory bowel disease and 4T1 tumor.

70 y unfit patients with quiescent Inflammatory Bowel Disease and can quickly achieve favourable body co

71 A role of sphingolipids for inflammatory bowel disease and cancer is evident.

72 implicated in diseases such as inflammatory bowel disease and cancer.

73 taining susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated wi

74 isk factor for pCCA followed by inflammatory bowel disease and cirrhosis, whereas other liver disease

75 Inflammatory bowel disease and colorectal cancer data sets were analy

76 regulation of DUOX2 and NOX1 in inflammatory bowel disease and colorectal cancer.

77 L-33, a cytokine upregulated in inflammatory bowel disease and helminth infection, induces intestinal

78 role in conditions ranging from inflammatory bowel disease and HIV through to sepsis and malnutrition

79 tool of pediatric patients with inflammatory bowel disease and in tissue sections of patients with CD

80 ound to differ in patients with inflammatory bowel disease and irritable bowel syndrome.

81 at multiple forms of arthritis, inflammatory bowel disease and myeloproliferative neoplasms, and nume

82 ediated diseases, most commonly inflammatory bowel disease and rheumatoid arthritis.

83 gitis, which is associated with inflammatory bowel disease and with an increased incidence of hepatob

84 eing developed for treatment of inflammatory bowel diseases and other immune-mediated diseases.

85 and colectomy in patients with inflammatory bowel diseases and PIPs.

86 enetical evidence linking PD to inflammatory bowel diseases and we recently demonstrated that the neu

87 , including multiple sclerosis, inflammatory bowel disease, and allergic disease.

88 erative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated w

89 erative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated

90 uding irritable bowel syndrome, inflammatory bowel disease, and colorectal cancer.

91 breast cancer, type 2 diabetes, inflammatory bowel disease, and coronary heart disease, all of which

92 ystemic lupus erythematosus and inflammatory bowel disease, and our previous work suggests that dysre

93 ein claudin-2 is upregulated in inflammatory bowel disease, and yet its deficit worsens infectious an

94 pact the modulation of colitis, inflammatory bowel diseases, and colorectal cancer.

95 ents as malabsorption syndrome, inflammatory bowel disease, anorexia nervosa, and intestinal pseudo-o

96 Inflammatory bowel diseases are associated with complex shifts in mic

97 Inflammatory bowel diseases are classic polygenic disorders, with gen

98 inflammatory disorders, such as inflammatory bowel disease, are major contributors to mortality and m

99 d, notably, to some humans with inflammatory bowel disease as a therapeutic agent that modulates infl

100 ed age and diagnoses other than inflammatory bowel disease as significant risk factors for mortality.

101 nsight into the pathogenesis of inflammatory bowel disease as well as new avenues to prevent and trea

102 tility disorders and may be useful for other bowel diseases as well.

103 us autoimmune diseases, such as inflammatory bowel disease, autoimmune thyroid disease, type 1 diabet

104 or neoplastic, diverticular, or inflammatory bowel disease between 2008 and 2015.

105 pathy have an increased risk of inflammatory bowel disease both before and after their nephropathy di

106 diseases, such as psoriasis and inflammatory bowel disease, but not in asthmatic patients, in whom fu

107 estigated in the development of inflammatory bowel diseases, cancer, metabolic syndrome, and neuropsy

108 s have revealed clusters of new inflammatory bowel disease cases amongst psoriasis patients using an

109 ative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and

110 lusion criteria were studies of inflammatory bowel disease cohorts, referrals for difficult polypecto

111 olitis, and 26 patients without inflammatory bowel diseases (control individuals).

112 and 10 newborn infants without inflammatory bowel diseases (controls) and 8 infants with necrotizing

113 t of self-care in patients with inflammatory bowel disease could allow targeted support and education

114 ncreased risk of developing the inflammatory bowel disease Crohn's disease, thus suggesting that the

115 tal role in the pathogenesis of inflammatory bowel diseases-Crohn disease and ulcerative colitis-caus

116 Inflammatory bowel disease data and ESKD status were obtained through

117 ropathy patients had an earlier inflammatory bowel disease diagnosis compared with 220 (1.09%) contro

118 the management of patients with inflammatory bowel disease during the coronavirus disease 2019 pandem

119 with IgA nephropathy, comorbid inflammatory bowel disease elevates the risk of progression to ESKD.

120 le in combatting the effects of inflammatory bowel disease, fistulae and ulcers.

121 Inflammatory bowel diseases frequently cause gastrointestinal dysmoti

122 t-based cohort of patients with inflammatory bowel disease, from November 2013 through June 2015.

123 he relationship between PSC and inflammatory bowel disease has inspired theories that intestinal fact

124 idence to suggest patients with inflammatory bowel disease have an increased risk of postoperative VT

125 Patients with inflammatory bowel disease have been shown to have abnormal brain mor

126 ceptibility genes implicated in inflammatory bowel disease (IBD) (Nod2 and Atg16l1) upon exposure to

127 g samples from individuals with inflammatory bowel disease (IBD) and healthy controls.

128 frican American population with inflammatory bowel disease (IBD) and Non-IBD/Non-Infectious Colitis (

129 cur frequently in patients with inflammatory bowel disease (IBD) and other mucosal disorders, but the

130 m-accelerated Il10-/- models of inflammatory bowel disease (IBD) and reduced elevated levels of pro-i

131 ified by the high prevalence of inflammatory bowel disease (IBD) and the even higher occurrence of su

132 observed both in patients with inflammatory bowel disease (IBD) and those with experimental colitis.

133 Patients with inflammatory bowel disease (IBD) are at increased risk of invasive pn

134 Plaque psoriasis and inflammatory bowel disease (IBD) are both chronic immune-mediated inf

135 nalysis on a published keystone inflammatory bowel disease (IBD) cohort and an in-house ulcerative co

136 mes from four human cohorts: an inflammatory bowel disease (IBD) cohort, an obese cohort and two popu

137 lcerative colitis (UC), and non-inflammatory bowel disease (IBD) controls.

138 The increased incidence of inflammatory bowel disease (IBD) has become a global phenomenon that

139 nts in patients with cancer and inflammatory bowel disease (IBD) has not been well described.

140 Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal

141 Studies of inflammatory bowel disease (IBD) have been inconclusive in relating m

142 Pediatric-onset colitis and inflammatory bowel disease (IBD) have significant effects on the grow

143 itable bowel syndrome (IBS) and inflammatory bowel disease (IBD) intersect to form a scantily defined

144 Inflammatory bowel disease (IBD) is a chronic complex disease of the

145 Inflammatory bowel disease (IBD) is a chronic disorder characterized

146 Inflammatory bowel disease (IBD) is a chronic immune-mediated disease

147 Inflammatory bowel disease (IBD) is a chronic inflammatory disease as

148 Inflammatory bowel disease (IBD) is a chronic inflammatory disease of

149 Inflammatory bowel disease (IBD) is a common chronic inflammatory con

150 Inflammatory bowel disease (IBD) is a complex genetic disease that is

151 Inflammatory bowel disease (IBD) is a complex multi-factorial disease

152 Inflammatory bowel disease (IBD) is a debilitating chronic disease wi

153 Inflammatory bowel disease (IBD) is an expanding autoimmune disease a

154 Inflammatory bowel disease (IBD) is associated with the production of

155 Childhood-onset inflammatory bowel disease (IBD) is believed to be a more severe dise

156 oscopy for clinically suspected inflammatory bowel disease (IBD) is not well defined, and its correla

157 Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine t

158 on and dysbiosis contributes to inflammatory bowel disease (IBD) pathogenesis.

159 yme production are hallmarks of inflammatory bowel disease (IBD) pathology.

160 activity are closely linked to inflammatory bowel disease (IBD) pathophysiology.

161 of Clostridioides difficile in inflammatory bowel disease (IBD) patients is a common occurrence, in

162 and corresponding mortality for inflammatory bowel disease (IBD) patients since the rise of biologic

163 stinal manifestations (EIMs) in inflammatory bowel disease (IBD) patients, and they are responsible f

164 vation promotes inflammation in inflammatory bowel disease (IBD) patients.

165 Patients with inflammatory bowel disease (IBD) present with reduced serum insulin-l

166 owever, the function of Arg1 in inflammatory bowel disease (IBD) remains poorly characterized.

167 ro study of the pathogenesis of inflammatory bowel disease (IBD) requires a cell model which closely

168 ay to integrate biomarkers into inflammatory bowel disease (IBD) research and clinical practice.

169 RS) may soon be used to predict inflammatory bowel disease (IBD) risk in prevention efforts.

170 Patients with inflammatory bowel disease (IBD) tend to avoid dairy products to mini

171 sis is a common complication of inflammatory bowel disease (IBD) that is usually the consequence of c

172 ase (CD) is a chronic relapsing inflammatory bowel disease (IBD) that may be marked by debilitating s

173 associated with the severity of inflammatory bowel disease (IBD)(2,5), the diverse immunomodulatory p

174 CRC), colonic lesions caused by inflammatory bowel disease (IBD), and normal thickened colon wall (NT

175 development and progression of inflammatory bowel disease (IBD), but determining generalizable effec

176 or iron-deficient patients with inflammatory bowel disease (IBD), but may be associated with hypophos

177 s a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient under

178 ses of the intestine, including inflammatory bowel disease (IBD), graft-versus-host disease (GVHD), a

179 tion resulting in autoimmunity, inflammatory bowel disease (IBD), hypogammaglobulinemia, regulatory T

180 Inflammatory bowel disease (IBD), including Crohn's disease (CD) and

181 are increased in patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcer

182 CRC), advanced adenoma (AA), or inflammatory bowel disease (IBD), is uncommon.

183 large cohorts of patients with inflammatory bowel disease (IBD), we have studied the intersections b

184 Complex diseases such as inflammatory bowel disease (IBD), which consists of ulcerative coliti

185 has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA)

186 xtraintestinal manifestation in inflammatory bowel disease (IBD), yet, the mechanisms driving gut-liv

187 down-regulated in patients with inflammatory bowel disease (IBD).

188 duces gut symptoms in quiescent inflammatory bowel disease (IBD).

189 ne-mediated diseases, including inflammatory bowel disease (IBD).

190 ant role in the pathogenesis of inflammatory bowel disease (IBD).

191 nflammatory diseases, including inflammatory bowel disease (IBD).

192 es pathogenetic mechanisms with inflammatory bowel disease (IBD).

193 th diagnosed celiac disease and inflammatory bowel disease (IBD).

194 e reproduction in patients with Inflammatory Bowel Disease (IBD).

195 al microbiome are implicated in inflammatory bowel disease (IBD).

196 k of serious infection in adult inflammatory bowel disease (IBD).

197 hy, ankylosing spondylitis, and inflammatory bowel disease (IBD).

198 s a possible oral treatment for inflammatory bowel disease (IBD).

199 as immunomodulatory therapy for inflammatory bowel disease (IBD).

200 in macrophages (Mphis) leads to inflammatory bowel disease (IBD).

201 hallmark in the pathogenesis of inflammatory bowel disease (IBD).

202 he epithelial barrier underpins inflammatory bowel disease (IBD).

203 nting symptoms of patients with inflammatory bowel disease (IBD).

204 langitis (PSC) in patients with inflammatory bowel disease (IBD).

205 ontrols (HCs) and patients with inflammatory bowel disease (IBD).

206 ntributes to the development of inflammatory bowel disease (IBD).

207 a novel susceptibility gene for inflammatory bowel disease (IBD).

208 Inflammatory Bowel Diseases (IBD) affect psychological, family, socia

209 Inflammatory bowel diseases (IBD) are associated with alterations in

210 Children with inflammatory bowel diseases (IBD) are particularly vulnerable to infe

211 nts seen at a tertiary academic inflammatory bowel diseases (IBD) clinic was compared to healthy volu

212 Inflammatory bowel diseases (IBD) develop via convergence of environm

213 herapeutic options for treating inflammatory bowel diseases (IBD) is increasing, evidence for rationa

214 Inflammatory bowel diseases (IBD), that includes ulcerative colitis a

215 linical outcomes of adults with inflammatory bowel diseases (IBD).

216 etween celiac disease (CeD) and inflammatory bowel diseases (IBD).

217 oholic fatty liver disease, and inflammatory bowel diseases (IBD).

218 a contribute to pathogenesis of inflammatory bowel diseases (IBD).

219 macrophages from patients with inflammatory bowel disease [IBD]) or mouse macrophages, respectively.

220 dysregulation in patients with inflammatory bowel diseases (IBDs) and differences in inflammatory re

221 Inflammatory bowel diseases (IBDs) exist worldwide, with high prevale

222 Patients with inflammatory bowel diseases (IBDs) have intestinal barrier dysfunctio

223 infants and young children with inflammatory bowel diseases (IBDs) have subtypes associated with a si

224 cestry, the epidemiology of the inflammatory bowel diseases (IBDs) is changing.

225 Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcera

226 tis are chronic and progressive inflammatory bowel diseases (IBDs) that are attributed to dysregulate

227 een proposed as a treatment for inflammatory bowel diseases (IBDs), but there are no established asso

228 For instance, in course of inflammatory bowel diseases (IBDs), in particular Crohn's Disease, as

229 Inflammatory bowel diseases (IBDs), including Crohn's disease and ulc

230 flammation and diseases such as inflammatory bowel diseases (IBDs), is often associated with dysbiosi

231 This is particularly evident in inflammatory bowel diseases (IBDs), where clinical trials of fecal mi

232 The inflammatory bowel diseases (IBDs), which include Crohn's disease (CD

233 RA; and 36.9 and 3.69 years for inflammatory bowel diseases (IBDs).

234 unosuppression for treatment of inflammatory bowel diseases (IBDs).

235 rdiopathy, renal insufficiency, inflammatory bowel disease, immunosuppression, anticoagulation, BMI>5

236 ere made in 2 patients (1%) and inflammatory bowel disease in 2 patients (1%).

237 ns in FAMIN cause arthritis and inflammatory bowel disease in early childhood, and a common genetic v

238 on cause serious infections and inflammatory bowel disease in glycogen storage disease type Ib (GSD-I

239 hazard ratios (HRs) for future inflammatory bowel disease in IgA nephropathy and conditional logisti

240 ssion to assess risk of earlier inflammatory bowel disease in IgA nephropathy.

241 Recent studies traced inflammatory bowel disease in some patients to deficiency of CD55 [de

242 ts of commensal bacteria induce inflammatory bowel diseases in genetically susceptible hosts.

243 n as a susceptibility factor in inflammatory bowel diseases in humans.

244 , the arthritis associated with inflammatory bowel disease including Crohn's disease and ulcerative c

245 suppressive therapy, such as in inflammatory bowel disease including ulcerative colitis and Crohn's d

246 ction have been associated with inflammatory bowel diseases, including ulcerative colitis (UC), but t

247 received infliximab therapy for inflammatory bowel diseases; infliximab-TNF complexes were measured w

248 genic or protective role during inflammatory bowel disease is controversial.

249 tasis and in the development of inflammatory bowel diseases is not fully understood.

250 of these data for the study of inflammatory bowel diseases is the absence of detailed clinical infor

251 y C13orf31) are associated with inflammatory bowel disease, leprosy, Behcet disease, and systemic juv

252 influencing type 2 diabetes and inflammatory bowel disease, making them good candidates for whole-exo

253 ss, insults commonly present in inflammatory bowel diseases, mediated the cyclic switch of cellular s

254 cause organic causes, including inflammatory bowel disease, microscopic colitis, and chronic infectio

255 sodium sulfate-induced chronic inflammatory bowel disease model, with efficacy similar to positive-c

256 TL1A, TNFSF15) is implicated in inflammatory bowel disease, modulating the location and severity of i

257 Male sex, young age at onset, small bowel disease, more active disease, and diagnostic delay

258 yalgia rheumatica (n = 25,581), inflammatory bowel disease (n = 27,739), rheumatoid arthritis (n = 25

259 e in various diseases including inflammatory bowel disease, neurologic diseases, cardiovascular disor

260 In particular, inflammatory bowel diseases, obesity, diabetes, asthma and chronic ob

261 ative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon a

262 or there is a family history of inflammatory bowel disease or coeliac disease.

263 gastrointestinal tract, such as inflammatory bowel disease or Cystic Fibrosis.

264 were enriched in patients with inflammatory bowel disease or cystic fibrosis.

265 ncontrolled inflammation due to inflammatory bowel disease or eosinophilic gastrointestinal disease s

266 -onset patients followed at our Inflammatory Bowel Disease outpatient clinic and compare with adult-o

267 ailure, chronic kidney disease, inflammatory bowel disease, patient blood management in the periopera

268 f ileal biopsies and PBMCs from inflammatory bowel disease patients, we identified a positive correla

269 en procedures for neoplasia and inflammatory bowel disease patients.

270 healthy individuals at risk for inflammatory bowel diseases (pre-UC) who later developed UC (post-UC)

271 high-risk patients (those with inflammatory bowel disease, previous CRC, previous multiple large pol

272 , systemic lupus erythematosus, inflammatory bowel disease, psoriasis, Sjogren syndrome, coronary art

273 ents with rheumatoid arthritis, inflammatory bowel diseases, psoriasis, or ankylosing spondylitis.

274 Q-5D], Short Quality of Life in Inflammatory Bowel Disease Questionnaire [SIBDQ], and Work Productivi

275 ive colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029,

276 e arterial system, lung perfusion, neoplasm, bowel diseases, renal calculi, tumor response to treatme

277 nfections, mucosal lesions, and inflammatory bowel disease resolved, and no symptomatic hypoglycemia

278 une diseases and schizophrenia: inflammatory bowel disease (rg = 0.12 +/- 0.03, P = 2.49 x 10-4), Cro

279 correlated with reduction of an inflammatory bowel disease risk gene ATG16L1 and Paneth cell lysozyme

280 e with lower bowel symptoms, but significant bowel disease (SBD), comprising colorectal cancer (CRC),

281 Older age at presentation, small bowel disease, serology (anti-Saccharomyces cerevisiae a

282 se the likelihood of finding an inflammatory bowel disease-specific fecal VOC marker profile.

283 from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP) were used.

284 fect of elevated IL18 levels on inflammatory bowel disease susceptibility (IBD) in 12,882 cases and 2

285 Crohn's disease is an inflammatory bowel disease that is characterized by chronic inflammat

286 ines how targeting RORgammat in inflammatory bowel disease therapy could influence the development of

287 In patients with inflammatory bowel disease, there is a breakdown of the multiple stra

288 to surveillance colonoscopy in inflammatory bowel disease to look at the different variables in this

289 ss the ability of patients with inflammatory bowel disease to perform routine self-care.

290 n an adoptive transfer model of inflammatory bowel disease, transfer of p73-deficient naive CD4(+) T

291 Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype ass

292 Very early onset inflammatory bowel disease (VEOIBD) denotes children with onset of IB

293 1.33 to 2.55) demonstrated that inflammatory bowel disease was associated with increased ESKD risk in

294 sitivity and the specificity for significant bowel disease were 96.1 and 26.2% with a positive and ne

295 No deaths or cases of inflammatory bowel disease were reported.

296 Patients with inflammatory bowel diseases who have postinflammatory polyps (PIPs) h

297 forms of disorders of the human inflammatory bowel disease with unknown etiologies.

298 g of the intestinal wall, secondary signs of bowel disease within the surrounding mesentery, and abno

299 alectin that has been linked to inflammatory bowel disease, within the context of the murine intestin

300 s like rheumatoid arthritis and inflammatory bowel disease yet increases susceptibility to tuberculos